John C.M. Farquhar Sells 22,562 Shares of Heartflow (NASDAQ:HTFL) Stock

Heartflow, Inc. (NASDAQ:HTFL) CEO John C.M. Farquhar sold 22,562 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $28.31, for a total transaction of $638,730.22. Following the completion of the transaction, the chief executive officer directly owned 436,280 shares of the company’s stock, valued at approximately $12,351,086.80. This trade represents a 4.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John C.M. Farquhar also recently made the following trade(s):

• On Friday, July 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The stock was sold at an average price of $27.75, for a total transaction of $626,095.50.
• On Wednesday, June 24th, John C.M. Farquhar sold 38,900 shares of Heartflow stock. The stock was sold at an average price of $35.00, for a total transaction of $1,361,500.00.
• On Wednesday, June 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The shares were sold at an average price of $28.50, for a total value of $643,017.00.

Heartflow Stock Up 1.0%

Shares of NASDAQ:HTFL traded up $0.31 during midday trading on Wednesday, reaching $29.85. The company had a trading volume of 1,081,029 shares, compared to its average volume of 1,418,309. Heartflow, Inc. has a 1-year low of $20.13 and a 1-year high of $41.22. The stock has a market cap of $2.57 billion and a PE ratio of -9.60. The business’s 50 day moving average price is $28.74 and its 200 day moving average price is $27.73.

Heartflow (NASDAQ:HTFL) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.08. The company had revenue of $52.59 million during the quarter. The firm’s quarterly revenue was up 41.3% compared to the same quarter last year. On average, research analysts expect that Heartflow, Inc. will post -0.82 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Wells Fargo & Company boosted their target price on shares of Heartflow from $35.00 to $37.00 and gave the stock an “overweight” rating in a report on Friday, May 15th. Piper Sandler reissued an “overweight” rating on shares of Heartflow in a research report on Thursday, June 11th. William Blair began coverage on shares of Heartflow in a research note on Monday, May 4th. They set an “outperform” rating on the stock. Freedom Capital raised shares of Heartflow to a “strong-buy” rating in a report on Tuesday, June 30th. Finally, Robert W. Baird initiated coverage on shares of Heartflow in a research note on Friday, July 31st. They issued an “outperform” rating and a $34.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $36.57.

Institutional Investors Weigh In On Heartflow

Hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. bought a new position in Heartflow during the third quarter worth $48,871,000. Legal & General Group Plc bought a new position in shares of Heartflow in the third quarter valued at about $59,000. Franklin Resources Inc. bought a new position in shares of Heartflow in the third quarter valued at about $10,829,000. UBS Group AG acquired a new stake in shares of Heartflow during the 3rd quarter worth about $5,130,000. Finally, Sei Investments Co. bought a new stake in shares of Heartflow during the 3rd quarter worth about $303,000.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.